Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2/3 1

Status

Unknown 3Terminated 1

Sponsor Class

NIH 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Pancreatic Neoplasms 4Lung Neoplasms 3Ovarian Neoplasms 2Endometrial Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Sarcoma 1Renal Insufficiency 1Recurrence 1Rectal Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Liver Diseases 1Leiomyosarcoma 1Gliosarcoma 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Breast Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Gemcitabine 683130-nm albumin-bound paclitaxel 198Fluorouracil 188Oxaliplatin 175Albumin-Bound Paclitaxel 154Capecitabine 137Leucovorin 131Irinotecan 112Radiotherapy 96Taxes 85pembrolizumab 81Cisplatin 72Erlotinib Hydrochloride 70Radiosurgery 69Nivolumab 56Drug Therapy 56Bevacizumab 54Magnetic Resonance Spectroscopy 50Cyclophosphamide 49folfirinox 45Specimen Handling 42Docetaxel 42Cetuximab 40irinotecan sucrosofate 38Biopsy 38S 1 (combination) 36Pancreaticoduodenectomy 35Blood Specimen Collection 34Surgical Procedures, Operative 31Paclitaxel 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × rubitecan × Clear all
NCT00113256 2024-08-02

Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer

Astex Pharmaceuticals, Inc.

Phase 2/3 Terminated
39 enrolled
Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

NCT00005869 2013-12-04

Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

National Cancer Institute (NCI)

Phase 3 Unknown
Gastrointestinal

Pancreatic Neoplasms

NCT00005870 2013-12-04

Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas

National Cancer Institute (NCI)

Phase 3 Unknown
Gastrointestinal

Pancreatic Neoplasms

NCT00005871 2013-12-04

Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer

National Cancer Institute (NCI)

Phase 3 Unknown
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡